Join me @ IBOtoolbox for free.
Vlad Tverdohleb
Member Since: 7/26/2015
  
performance / stats
Country: Canada
Likes Received: 120
Featured Member: 0 times
Associates: 115
Wall Posts: 308
Comments Made: 41
Press Releases: 296
Videos: 0
Phone: 015144814545
Skype:     theprservices
profile visitor stats
TODAY: 83
THIS MONTH: 1727
TOTAL: 59950
are we ibo associates?
recent videos
member advertising
none
active associates
Whitney Jacqueline       
Last logged on: 10/18/2018


Csaba Juhasz    
Last logged on: 10/18/2018


Sharon Naraine    
Last logged on: 10/18/2018


Bruno Duarte    
Last logged on: 10/18/2018


Tracy Carter     
Last logged on: 10/18/2018


Todd Treharne    
Last logged on: 10/18/2018


Athena Gay    
Last logged on: 10/18/2018


Chauncey Penfold    
Last logged on: 10/18/2018


Chuck Reynolds    
Last logged on: 10/18/2018


Phil Schaefer    
Last logged on: 10/18/2018


PHIL SCHAEFER    
Last logged on: 10/18/2018


Steven Anthony    
Last logged on: 10/18/2018


Eugenijus Sakalauskas    
Last logged on: 10/18/2018


Marlena Burton    
Last logged on: 10/18/2018


William OToole     
Last logged on: 10/18/2018


other ibo platforms
Vlad Tverdohleb   My Press Releases

The FDA Puts the Brakes on A Major CRISPR Trial in Humans

Published on 6/3/2018
For additional information  Click Here

You’ve heard it before: CRISPR has the potential to change our lives for the better. But first, we have to give it a chance.

In December, gene-editing company CRISPR Therapeutics announced a partnership with biotech company Vertex to develop CTX001, the world’s first gene-based treatment for sickle cell disease (SCD). Now, the U.S. Food and Drug Administration (FDA) has denied the companies’ request to move forward with a early-phase trial of CTX001 in adult volunteers, placing a “clinical hold” on the application.

According to a CRISPR Therapeutics press release, the FDA has “certain questions” it wants resolved before it gives the go-ahead to the human CRISPR study. The company appears to be waiting for additional information on those questions and plans to resolve them “rapidly.”

 

SCD is a genetic blood disorder in which a protein in red blood cells called hemoglobin doesn’t transport oxygen throughout the body the way it should. This can cause a host of health problems, from chronic pain to blindness to strokes.

When we’re born, our blood contains a different version of hemoglobin known as fetal hemoglobin (HbF). Usually, the adult version of hemoglobin replaces HbF post-birth, but sometimes HbF remains in the blood through adulthood. When that happens to a person with SCD, it can reduce the severity of their symptoms.

CTX001 is intended to replicate this rare fluke of nature in patients. The first step in the therapy is to extract cells from the patient. Then, the researcher genetically edits the cells in the lab to produce significant amounts of HbF. Finally, they reintroduce the cells to the patient’s body where they generate new red blood cells with higher levels of HbF.

 

The lab results have at least been promising enough for the researchers to move towards human studies. But until they get the go-ahead to move forward with their human CRISPR study, we can’t know for sure whether CTX001 will work as expected.

This trial, should it move forward, won’t be the first time CRISPR has been tested in humans — that first try was in China in 2016. But this trial would mark one of the first to happen in the U.S., as MIT Tech Review reports(several others, including some to treat SCD, are also moving forward, and it’s not clear which group will get there first).

Read more here.

Member Note: To comment on this PR, simply click reply on the owners main post below.
-  Copyright 2016 IBOsocial  -            Part of the IBOtoolbox family of sites.